Trial 1B-23-5


An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07220060 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Participants Over 18 Years of Age with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Biological Response Modifier, Other
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Daphne Stewart, M.D.
Other Trial Staff:  Marissa Aldana, Coordinator, Mary Ordaz, D.M., Margarita Carranza, D.M., America Casillas-Lopez, Coordinator, Niranjan Bhatt, D.M., Apoorva Vishwanath, D.M., Othesia Glasgow, D.M., Maria Kaufman, Coordinator, Kimberly Arieli, Coordinator, Alejandro Baltazar, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.